Business
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":"Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation provides first look at IMR-261, a novel oral Nrf2 activator shown to reactivate fetal hemoglobin and reduce VOCs in preclinical models of sickle cell disease and increase hemoglobin in a preclinical model of beta-thalassemia BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that it will present clinical and preclinical data at the American Society of Hematology (ASH) Annual Meeting to be held December 11-14, 2021. “We look forward to reporting updated 12-month VOC data from our Phase 2a open label extension trial of tovinontrine (IMR-687) in adults with sickle cell disease as well as data in preclinical models of beta-thalassemia,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “In addition, we are excited to share this first look at IMR-261, a new asset in our development pipeline. IMR-261 is a clinic-ready oral activator of nuclear factor erythroid 2–related factor 2, or Nrf2. In pre-clinical models of SCD, IMR-261 was observed to reactivate fetal hemoglobin and reduce vaso-occlusive crises. Furthermore, in a preclinical model of beta-thalassemia, IMR-261 was observed to increase hemoglobin and enhance red blood cell maturation. We have initiated work towards drug product manufacturing for IMR-261, as we explore potential clinical development paths.” IMR-261, formerly known as CXA-10, was acquired by Imara and was previously evaluated by Complexa, Inc. in Phase 2 clinical trials in focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Independent medical literature suggests potential promise in a broad array of red cell diseases, including disorders of hemoglobin. The accepted abstracts are listed below and are available online on the ASH meeting library website. Title: PDE9 Inhibition By IMR-687 Improves Markers of Beta-Thalassemia in the Hbb th1/th1 Experimental Mouse ModelLive Q&A Session Date and Time: Saturday, December 11, 2021,...